Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...